Type 2 & other diabetes

BMI variability and cardiovascular outcomes within clinical trial and real-world environments in type 2 diabetes: an IMI2 SOPHIA study

Cardiovasc DiabetolPublished Post hoc analysis of cardiovascular outcome trials and real-world cohort

Primary result · 3P-MACE per +1 SD increase in BMI variability (Harmony Outcomes)Result — go to the resultHazard ratio 1.12 95% CI 1.08–1.17

Authors' conclusion

In individuals with type 2 diabetes, increased BMI variability was found to be an independent risk factor for 3P-MACE across cardiovascular outcome trials and real-world datasets. Future research should attempt to establish a causal relationship between BMI variability and cardiovascular outcomes.

Study context

Population
Individuals with T2D in Harmony Outcomes, placebo arms of REWIND and EMPA-REG OUTCOME, and the Tayside Bioresource
Participants
9,198 / 4,440 / 2,333 / 6,980
Comparison
Higher vs lower BMI variability
  • Harmony Outcomesn = 9,198
  • REWINDn = 4,440
  • EMPA-REG OUTCOMEn = 2,333
  • Tayside Bioresourcen = 6,980
Primary endpoint
First 3P-MACE: non-fatal stroke, non-fatal MI or cardiovascular death
Methodological detailsCox regression, adjusted for cardiovascular risk factors
  • Cox regression
  • Adjusted for cardiovascular risk factors

Primary result

As reported in the abstract

3P-MACE per +1 SD increase in BMI variability (Harmony Outcomes)

Hazard ratio

1.12

95% CI 1.08–1.17

P < 0.001

+1 SD BMI variability
HR 1.12 (95% CI 1.08–1.17); P < 0.001

Per +1 SD increase in BMI variability, as printed

Further findings

3P-MACE, most vs least variable BMI quartile (Harmony Outcomes)

Most variable quartile had higher 3P-MACE risk vs least variable (P < 0.001)
87%

Replication in other cohorts

Similar associations in REWIND and Tayside Bioresource
Not replicated in EMPA-REG OUTCOME
Effect independent of HbA1c variability

Original publication

BMI variability and cardiovascular outcomes within clinical trial and real-world environments in type 2 diabetes: an IMI2 SOPHIA study. Cardiovasc Diabetol. Published 16 July 2024. doi:10.1186/s12933-024-02299-8

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.